Day One Biopharmaceuticals Inc [NASDAQ: DAWN] closed the trading session at $9.14 on 2025-11-05. The day’s price range saw the stock hit a low of $7.905, while the highest price level was $9.98.
The stocks have a year to date performance of -37.61 percent and weekly performance of 29.83 percent. The stock has been moved at 45.08 percent over the last six months. The stock has performed 23.35 percent around the most recent 30 days and changed 51.58 percent over the most recent 3-months.
If compared to the average trading volume of 1.55M shares, DAWN reached to a volume of 10491597 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Day One Biopharmaceuticals Inc [DAWN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DAWN shares is $23.78 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DAWN stock is a recommendation set at 1.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Day One Biopharmaceuticals Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on August 19, 2025. While these analysts kept the previous recommendation, Needham raised their target price from $32 to $33. The new note on the price target was released on October 09, 2024, representing the official price target for Day One Biopharmaceuticals Inc stock. Previously, the target price had yet another raise from $11 to $24, while BofA Securities kept a Buy rating on DAWN stock. On April 24, 2024, analysts increased their price target for DAWN shares from 30 to 33.
The Price to Book ratio for the last quarter was 2.08, with the Price to Cash per share for the same quarter was set at 4.41.
DAWN stock trade performance evaluation
Day One Biopharmaceuticals Inc [DAWN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 29.83. With this latest performance, DAWN shares gained by 23.35% in over the last four-week period, additionally plugging by 45.08% over the last 6 months – not to mention a drop of -27.86% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DAWN stock in for the last two-week period is set at 71.91, with the RSI for the last a single of trading hit 0.64, and the three-weeks RSI is set at 0.49 for Day One Biopharmaceuticals Inc [DAWN]. The present Moving Average for the last 50 days of trading for this stock 7.31, while it was recorded at 7.65 for the last single week of trading, and 7.80 for the last 200 days.
Day One Biopharmaceuticals Inc [DAWN]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Day One Biopharmaceuticals Inc [DAWN] shares currently have an operating margin of -123.90% and a Gross Margin at 89.44%. Day One Biopharmaceuticals Inc’s Net Margin is presently recorded at -113.53%.
Day One Biopharmaceuticals Inc (DAWN) Capital Structure & Debt Analysis
According to recent financial data for Day One Biopharmaceuticals Inc. ( DAWN), the Return on Equity (ROE) stands at -30.16%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -27.23%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Day One Biopharmaceuticals Inc’s Return on Invested Capital (ROIC) is -33.46%, showcasing its effectiveness in deploying capital for earnings.
Day One Biopharmaceuticals Inc (DAWN) Efficiency & Liquidity Metrics
Based on Day One Biopharmaceuticals Inc’s (DAWN) latest financial statements, the Debt-to-Equity Ratio is 0.01%, indicating its reliance on debt financing relative to shareholder equity.
Day One Biopharmaceuticals Inc (DAWN) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Day One Biopharmaceuticals Inc. (DAWN) effectively leverages its workforce, generating an average of -$838453.04 per employee. The company’s liquidity position is robust, with a Current Ratio of 8.68% and a Quick Ratio of 8.55%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Day One Biopharmaceuticals Inc [DAWN] stock
With the latest financial reports released by the company, Day One Biopharmaceuticals Inc posted -0.63/share EPS, while the average EPS was predicted by analysts to be reported at -0.35/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.28. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DAWN.
Day One Biopharmaceuticals Inc [DAWN]: Institutional Ownership
There are presently around $86.20%, or 103.77%% of DAWN stock, in the hands of institutional investors. The top three institutional holders of DAWN stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 7.87 million shares, which is approximately 9.0354%. ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC, holding 6.43 million shares of the stock with an approximate value of $$88.61 million in DAWN stocks shares; and ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC, currently with $$63.71 million in DAWN stock with ownership which is approximately 5.3067%.
